Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • PRMT5 Inhibition Reveals Glutamine Metabolic Vulnerability i

    2026-06-12

    Spliceosomal and Metabolic Vulnerabilities in MYCN-Amplified Neuroblastoma: Insights from PRMT5 Inhibition

    Study Background and Research Question

    High-risk neuroblastoma, particularly those with MYCN gene amplification, represents a major clinical challenge in pediatric oncology. Approximately half of poor prognosis neuroblastoma cases are driven by excessive MYCN expression, leading to aggressive disease and less than 40% long-term survival rates in affected patients. Previous research established a functional interplay between MYCN and PRMT5, an arginine methyltransferase implicated in epigenetic regulation and splicing. However, the precise molecular basis through which PRMT5 influences MYCN-amplified (MNA) neuroblastoma cell survival—especially regarding metabolic and transcriptomic regulation—remained inadequately understood. The central question addressed by Bojko et al. (Cancer Lett. 2024) is: How does PRMT5 inhibition expose vulnerabilities in the splicing machinery and metabolic pathways of MNA neuroblastoma, and what are the mechanistic underpinnings of this sensitivity?

    Key Innovation from the Reference Study

    The central innovation lies in dissecting the dual role of PRMT5 in orchestrating both spliceosomal function and metabolic pathway regulation within MYCN-driven neuroblastomas. Using selective PRMT5 inhibitors (GSK3203591 in vitro, GSK3326593 in vivo), the researchers uncovered that PRMT5 loss not only perturbs RNA splicing—leading to widespread intron retention and transcriptome rewiring—but also disrupts glutamine metabolism, a critical metabolic dependency in these tumors. This convergence of spliceosomal and metabolic disruption creates a unique vulnerability in MNA neuroblastoma, offering new translational entry points for targeted intervention.

    Methods and Experimental Design Insights

    The study employed a multi-layered experimental approach combining cell biology, genomics, metabolomics, and in vivo modeling:

    • Selective inhibition of PRMT5 was achieved using GSK3203591 in neuroblastoma cell lines and GSK3326593 in Th-MYCN transgenic mouse models.
    • Cell viability, proliferation, and apoptosis were quantified in both MYCN-amplified and non-amplified neuroblastoma lines to assess differential drug sensitivity.
    • RNA sequencing (RNA-seq) was performed post-inhibitor treatment to map splicing alterations, with special attention to genes involved in DNA damage response, epitranscriptomics, and cellular metabolism.
    • Stable isotope labelling tracked glutamine flux and associated metabolite changes, revealing PRMT5’s impact on glutamine utilization.
    • Protein and mRNA analyses (including m6A methylation quantification) elucidated the regulatory cascade linking PRMT5 inhibition to glutaminase (GLS1) protein suppression.
    • In vivo efficacy was validated by treating Th-MYCN mice and evaluating survival outcomes alongside molecular readouts consistent with in vitro findings.

    Protocol Parameters

    • PRMT5 inhibitor (GSK3203591) treatment: MYCN-amplified neuroblastoma cell lines treated at concentrations yielding maximal growth inhibition and apoptosis, e.g., nanomolar range for 24–72 hours.
    • RNA-seq sampling: Cells harvested after 24–48 hours of PRMT5 inhibition to capture acute splicing and transcriptional changes.
    • Stable isotope tracing: [U-13C]-glutamine used to quantify metabolic flux before and after PRMT5 inhibition.
    • In vivo validation: Th-MYCN transgenic mice administered GSK3326593 according to preclinical dosing regimens, with survival and molecular endpoints monitored.

    Core Findings and Why They Matter

    Bojko et al. show that MYCN-amplified neuroblastoma cells are approximately 200-fold more sensitive to PRMT5 inhibition compared to non-amplified lines. PRMT5 blockade led to widespread disruption of the splicing program, particularly affecting transcripts related to the DNA damage response, epitranscriptomic machinery, and cellular metabolic processes (Cancer Lett. 2024).

    A major mechanistic insight is that PRMT5 inhibition impairs the splicing of MLX (a nutrient sensing transcription factor), leading to reduced MLX/Mondo signaling and direct disruption of glutamine metabolism. Stable isotope labeling confirmed a marked reduction in glutaminolysis, with glutaminase (GLS1) protein levels dropping post-treatment despite stable transcript levels. This discrepancy was traced to altered m6A RNA methylation: splicing changes in METTL3 and YTHDF3 (an m6A reader) led to lower protein abundance, diminishing m6A modification of GLS1 mRNA and reducing GLS1 translation. Knockdown of YTHDF3 alone replicated the glutaminase protein decrease, confirming epitranscriptomic control.

    In vivo, PRMT5 inhibition significantly extended survival in Th-MYCN neuroblastoma mice, validating translational potential. These results highlight a previously unappreciated intersection between splicing, epitranscriptomics, and metabolic regulation in neuroblastoma, offering a rationale for dual targeting strategies in cancer metabolism research.

    Comparison with Existing Internal Articles

    Recent reviews and best-practice guides on glutaminolysis inhibition, such as CB-839 (Telaglenastat): Precision Glutaminolysis Inhibition in Cancer Research and Rethinking Glutamine Metabolism in Oncology, emphasize the centrality of glutaminase inhibitors in preclinical cancer drug evaluation. However, the reference study by Bojko et al. advances this field by linking glutamine metabolism disruptions directly to splicing and epitranscriptomic machinery, rather than solely to metabolic enzyme activity. This integrative mechanistic view provides a new framework for interpreting results from glutaminolysis inhibition assays and suggests that assays incorporating spliceosomal and m6A regulatory endpoints may yield deeper mechanistic insights.

    The internal article PRMT5-Driven Splicing and Metabolic Vulnerabilities in MYCN Neuroblastoma offers an accessible summary of the reference paper’s core message, contextualizing the convergence of splicing, epitranscriptomics, and metabolism in actionable preclinical workflows.

    Limitations and Transferability

    While the study robustly demonstrates PRMT5-dependent vulnerabilities in MYCN-amplified neuroblastoma, several limitations merit consideration:

    • The pronounced sensitivity to PRMT5 inhibition was observed in cell lines and transgenic mouse models with MYCN amplification; transferability to other neuroblastoma genotypes or non-neural solid tumors remains to be established.
    • Although the molecular cascade from PRMT5 to GLS1 suppression is well supported, the broader impact on the tumor microenvironment and potential resistance mechanisms were not addressed.
    • Translational relevance will require further validation in diverse patient-derived xenografts and, ultimately, clinical samples.

    Nonetheless, the mechanistic insights into PRMT5’s dual role in splicing and metabolism create a foundation for future studies targeting these axes in preclinical cancer metabolism research and drug development.

    Research Support Resources

    Researchers aiming to model glutaminolysis inhibition and metabolic vulnerabilities in neuroblastoma or other cancer types can utilize selective glutaminase 1 inhibitors such as CB-839 (Telaglenastat) (SKU B4799), which enables precise disruption of glutamine metabolism in cell-based and in vivo assays. As detailed in the product information, CB-839 is orally bioavailable, highly selective, and widely used for mechanistic studies of glutaminolysis, autophagy induction in cancer cells, and preclinical cancer drug evaluation. For workflow optimization and protocol refinements, researchers may also consult internal guides such as Optimizing Cancer Metabolism Assays, which provide troubleshooting strategies and recent innovations for maximizing reproducibility and translational relevance.